Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are suggested to be responsible for drug resistance and cancer relapse due in part to their ability to self-renew themselves and differentiate into heterogeneous lineages of cancer cells. Thus, it is important to understand the characteristics and mechanisms by which CSCs display resistance to therapeutic agents. In this review, we highlight the key features and mechanisms that regulate CSC function in drug resistance as well as recent breakthroughs of therapeutic approaches for targeting CSCs. This promises new insights of CSCs in drug resistance and provides better therapeutic rationales to accompany novel anticancer therapeutics
Surgery, radiotherapy and chemotherapy are universally recognized as the most effective anti-cancer ...
Abstract Some cancers like melanoma and pancreatic and ovarian cancers, for example, c...
Different mechanisms contribute to intratumor heterogeneity, including genetic mutations, the microe...
Resistance to tumor therapy is an unsolved problem in cancer treatment. A plethora of studies have a...
Introduction: Several reports have suggested that a population of undifferentiated cells known as ca...
Resistance to chemotherapy and cancer relapse are major clinical challenges attributed to a sub popu...
Drug resistance represents one of the greatest challenges in cancer treatment. Cancer stem cells (CS...
Resistance to cancer therapy remains a significant obstacle in treating patients with various solid ...
Tumors pose a significant threat to human health. Although many methods, such as operations, chemoth...
Immunotherapy is an emerging form of cancer therapy that is associated with promising outcomes. Howe...
Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are elucidated as cells that ...
The therapeutic limitations of conventional chemotherapeutic drugs present a challenge for cancer th...
Cancer stem cells (CSCs) have provided new insights into the tumorigenesis and metastatic potential ...
Cancer stem cells (CSCs) are gaining prominence in oncology. The characterization of the molecular p...
Abstract Conspicuous investigations have proven the role of cancer stem cells (CSCs) in the onset an...
Surgery, radiotherapy and chemotherapy are universally recognized as the most effective anti-cancer ...
Abstract Some cancers like melanoma and pancreatic and ovarian cancers, for example, c...
Different mechanisms contribute to intratumor heterogeneity, including genetic mutations, the microe...
Resistance to tumor therapy is an unsolved problem in cancer treatment. A plethora of studies have a...
Introduction: Several reports have suggested that a population of undifferentiated cells known as ca...
Resistance to chemotherapy and cancer relapse are major clinical challenges attributed to a sub popu...
Drug resistance represents one of the greatest challenges in cancer treatment. Cancer stem cells (CS...
Resistance to cancer therapy remains a significant obstacle in treating patients with various solid ...
Tumors pose a significant threat to human health. Although many methods, such as operations, chemoth...
Immunotherapy is an emerging form of cancer therapy that is associated with promising outcomes. Howe...
Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are elucidated as cells that ...
The therapeutic limitations of conventional chemotherapeutic drugs present a challenge for cancer th...
Cancer stem cells (CSCs) have provided new insights into the tumorigenesis and metastatic potential ...
Cancer stem cells (CSCs) are gaining prominence in oncology. The characterization of the molecular p...
Abstract Conspicuous investigations have proven the role of cancer stem cells (CSCs) in the onset an...
Surgery, radiotherapy and chemotherapy are universally recognized as the most effective anti-cancer ...
Abstract Some cancers like melanoma and pancreatic and ovarian cancers, for example, c...
Different mechanisms contribute to intratumor heterogeneity, including genetic mutations, the microe...